Business
HCW Biologics Announces Appointment of Two New Members to Board of Directors
New Members Add Depth to Board with Experience in Strategic Transactions, Strategy and Commercial Planning, and Governance MIRAMAR, Fla., Oct. 27, 2021 (GLOBE
About this update from Hcw Biologics Inc.
[{"type":"text","content":"New Members Add Depth to Board with Experience in Strategic Transactions, Strategy and Commercial Planning, and Governance\nMIRAMAR, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today announced the appointment of two new independent directors, Lisa M. Giles and Gary M. Winer, to its Board of Directors, effective immediately. The appointments expand the Company’s Board to five members, four of whom are independent directors. “Adding individuals with Lisa’s and Gary’s extensive talents and corporate experience in the life sciences industry is an important achievement for our Company and stockholders that we believe will contribute greatly to our long-term success,” said Hing C. Wong, Ph.D., founder and CEO of HCW Biologics. “Gary and Lisa have long, successful careers building life sciences businesses and serving in senior management roles. On behalf of the Board, I am pleased to welcome them to HCW Biologics and look forward to benefitting from their knowledge and expertise.” Ms. Giles and Mr. Winer will both serve on the Board’s audit committee, chaired by Rick S. Greene, and the Board’s compensation committee, chaired by Scott T. Garrett. Dr. Wong will step down from the audit committee but remain a member of the Board of Directors. Mr. Garrett will continue as Chairman of the Board of Directors. Ms. Giles commented, “Under Dr. Wong’s leadership, HCW stands at the vanguard in the development of a new generation of immunotherapeutics that address the age-related disorders associated with chronic inflammation. The Company’s recent initial public offering and the expected advancement of its lead drug candidate, HCW9218, into clinical trials are exciting opportunities for patients and HCW’s growth, one that could deliver significant stockholder value. I look forward to working with Dr. Wong, the leadership team and the other Board members as HCW advances its clinical development portfolio.” Mr. Winer commented, “I am eager to work with Dr. Wong and the other Board members to help HCW Biologics achieve its full potential. As the Company continues to advance the development of i...